Cronos Group Inc banner

Cronos Group Inc
TSX:CRON

Watchlist Manager
Cronos Group Inc Logo
Cronos Group Inc
TSX:CRON
Watchlist
Price: 3.53 CAD -0.84%
Market Cap: CA$1.4B

Relative Value

The Relative Value of one CRON stock under the Base Case scenario is hidden CAD. Compared to the current market price of 3.53 CAD, Cronos Group Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CRON Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

CRON Competitors Multiples
Cronos Group Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Cronos Group Inc
TSX:CRON
1.4B CAD 7.5 27.4 -25.1 -8.4
US
Eli Lilly and Co
NYSE:LLY
991.1B USD 15.2 48 32.4 34.4
US
Johnson & Johnson
NYSE:JNJ
588.6B USD 6.3 22 15.3 18.7
CH
Roche Holding AG
SIX:ROG
286.4B CHF 4.7 30.4 12.8 15
UK
AstraZeneca PLC
LSE:AZN
232.4B GBP 5.5 34.2 16.3 23.8
CH
Novartis AG
SIX:NOVN
236.9B CHF 5.4 21.8 13.4 17.2
US
Merck & Co Inc
NYSE:MRK
300.6B USD 4.6 16.5 10.3 12
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.3 9.8 11.5
US
Pfizer Inc
NYSE:PFE
157B USD 2.5 20.3 7.5 10.1
US
Bristol-Myers Squibb Co
NYSE:BMY
123.4B USD 2.6 17.5 6.8 8.8
P/E Multiple
Earnings Growth PEG
CA
Cronos Group Inc
TSX:CRON
Average P/E: 25.1
27.4
2%
13.7
US
Eli Lilly and Co
NYSE:LLY
48
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22
7%
3.1
CH
Roche Holding AG
SIX:ROG
30.4
29%
1
UK
AstraZeneca PLC
LSE:AZN
34.2
38%
0.9
CH
Novartis AG
SIX:NOVN
21.8
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.5
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
7%
1.9
US
Pfizer Inc
NYSE:PFE
20.3
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.5
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Cronos Group Inc
TSX:CRON
Average EV/EBITDA: 45.8
Negative Multiple: -25.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.4
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.3
2%
7.6
CH
Roche Holding AG
SIX:ROG
12.8
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
16.3
10%
1.6
CH
Novartis AG
SIX:NOVN
13.4
9%
1.5
US
Merck & Co Inc
NYSE:MRK
10.3
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
7%
1.4
US
Pfizer Inc
NYSE:PFE
7.5
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.8
-13%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Cronos Group Inc
TSX:CRON
Average EV/EBIT: 98.7
Negative Multiple: -8.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.4
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.7
6%
3.1
CH
Roche Holding AG
SIX:ROG
15
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
23.8
23%
1
CH
Novartis AG
SIX:NOVN
17.2
12%
1.4
US
Merck & Co Inc
NYSE:MRK
12
6%
2
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
8%
1.4
US
Pfizer Inc
NYSE:PFE
10.1
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-6%
N/A